These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 22467661)

  • 1. Human Vγ9Vδ2 T cells specifically recognize and kill acute myeloid leukemic blasts.
    Gertner-Dardenne J; Castellano R; Mamessier E; Garbit S; Kochbati E; Etienne A; Charbonnier A; Collette Y; Vey N; Olive D
    J Immunol; 2012 May; 188(9):4701-8. PubMed ID: 22467661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel nonradioactive CFDA assay to monitor the cellular immune response in myeloid leukemia.
    Yang T; Chen ZZ; Kolb HJ; Buhmann R
    Immunobiology; 2013 Apr; 218(4):548-53. PubMed ID: 22883564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absence of class II-associated invariant chain peptide on leukemic blasts of patients promotes activation of autologous leukemia-reactive CD4+ T cells.
    van Luijn MM; van den Ancker W; Chamuleau ME; Zevenbergen A; Westers TM; Ossenkoppele GJ; van Ham SM; van de Loosdrecht AA
    Cancer Res; 2011 Apr; 71(7):2507-17. PubMed ID: 21310823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flow cytometric assessment of autologous gammadelta T cells in patients with acute myeloid leukemia: potential effector cells for immunotherapy?
    Aswald JM; Wang XH; Aswald S; Lutynski A; Minden MD; Messner HA; Keating A
    Cytometry B Clin Cytom; 2006 Nov; 70(6):379-90. PubMed ID: 16977635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comprehensive analysis of primary acute myeloid leukemia identifies biomarkers predicting susceptibility to human allogeneic Vγ9Vδ2 T cells.
    Gundermann S; Klinker E; Kimmel B; Flierl U; Wilhelm M; Einsele H; Kunzmann V
    J Immunother; 2014; 37(6):321-30. PubMed ID: 24911793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activated natural killer cells from patients with acute myeloid leukemia are cytotoxic against autologous leukemic blasts in NOD/SCID mice.
    Siegler U; Kalberer CP; Nowbakht P; Sendelov S; Meyer-Monard S; Wodnar-Filipowicz A
    Leukemia; 2005 Dec; 19(12):2215-22. PubMed ID: 16224486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute myeloid leukemia (AML)-reactive cytotoxic T lymphocyte clones rapidly expanded from CD8(+) CD62L((high)+) T cells of healthy donors prevent AML engraftment in NOD/SCID IL2Rgamma(null) mice.
    Distler E; Wölfel C; Köhler S; Nonn M; Kaus N; Schnürer E; Meyer RG; Wehler TC; Huber C; Wölfel T; Hartwig UF; Herr W
    Exp Hematol; 2008 Apr; 36(4):451-63. PubMed ID: 18261837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNAX accessory molecule-1 (CD226) promotes human hepatocellular carcinoma cell lysis by Vgamma9Vdelta2 T cells.
    Toutirais O; Cabillic F; Le Friec G; Salot S; Loyer P; Le Gallo M; Desille M; de La Pintière CT; Daniel P; Bouet F; Catros V
    Eur J Immunol; 2009 May; 39(5):1361-8. PubMed ID: 19404979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL-23R and TCR signaling drives the generation of neonatal Vgamma9Vdelta2 T cells expressing high levels of cytotoxic mediators and producing IFN-gamma and IL-17.
    Moens E; Brouwer M; Dimova T; Goldman M; Willems F; Vermijlen D
    J Leukoc Biol; 2011 May; 89(5):743-52. PubMed ID: 21330350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved effector function of leukemia-specific T-lymphocyte clones trained with AML-derived dendritic cells.
    Schuster FR; Buhmann R; Reuther S; Hubner B; Grabrucker C; Liepert A; Reibke R; Lichtner P; Yang T; Kroell T; Kolb HJ; Borkhardt A; Schmetzer H
    Cancer Genomics Proteomics; 2008; 5(5):275-86. PubMed ID: 19129558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of autologous leukemia-specific T cells in acute myeloid leukemia: monocyte-derived dendritic cells cocultured with leukemic blasts compared with leukemia-derived dendritic cells.
    Draube A; Beyer M; Wolf J
    Eur J Haematol; 2008 Oct; 81(4):281-8. PubMed ID: 18573171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of death (CD95/FAS), activation and adhesion (CD54) molecules on blast cells of acute myelogenous leukemias by TNF-alpha and IFN-gamma.
    Munker R; Andreeff M
    Cytokines Mol Ther; 1996 Sep; 2(3):147-59. PubMed ID: 9384699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The CD226-ERK1/2-LAMP1 pathway is an important mechanism for Vγ9Vδ2 T cell cytotoxicity against chemotherapy-resistant acute myeloid leukemia blasts and leukemia stem cells.
    Wu K; Wang LM; Liu M; Xiu Y; Hu Y; Fu S; Huang H; Xu B; Xiao H
    Cancer Sci; 2021 Aug; 112(8):3233-3242. PubMed ID: 34107135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristic of TIGIT and DNAM-1 Expression on Foxp3+
    Jin Z; Ye W; Lan T; Zhao Y; Liu X; Chen J; Lai J; Chen S; Zhong X; Wu X
    Biomed Res Int; 2020; 2020():4612952. PubMed ID: 32802845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical grade expansion of CD45RA, CD45RO, and CD62L-positive T-cell lines from HLA-compatible donors: high cytotoxic potential against AML and ALL cells.
    Barbui AM; Borleri G; Conti E; Ciocca A; Salvi A; Micò C; Introna M; Rambaldi A
    Exp Hematol; 2006 Apr; 34(4):475-85. PubMed ID: 16569594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The quality and quantity of leukemia-derived dendritic cells from patients with acute myeloid leukemia and myelodysplastic syndrome are a predictive factor for the lytic potential of dendritic cells-primed leukemia-specific T cells.
    Grabrucker C; Liepert A; Dreyig J; Kremser A; Kroell T; Freudenreich M; Schmid C; Schweiger C; Tischer J; Kolb HJ; Schmetzer H
    J Immunother; 2010 Jun; 33(5):523-37. PubMed ID: 20463595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leukemia-specific T-cell reactivity induced by leukemic dendritic cells is augmented by 4-1BB targeting.
    Houtenbos I; Westers TM; Dijkhuis A; de Gruijl TD; Ossenkoppele GJ; van de Loosdrecht AA
    Clin Cancer Res; 2007 Jan; 13(1):307-15. PubMed ID: 17170077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Partial and ineffective activation of V gamma 9V delta 2 T cells by Mycobacterium tuberculosis-infected dendritic cells.
    Meraviglia S; Caccamo N; Salerno A; Sireci G; Dieli F
    J Immunol; 2010 Aug; 185(3):1770-6. PubMed ID: 20592281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts.
    Le Dieu R; Taussig DC; Ramsay AG; Mitter R; Miraki-Moud F; Fatah R; Lee AM; Lister TA; Gribben JG
    Blood; 2009 Oct; 114(18):3909-16. PubMed ID: 19710498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemokine receptors expression and migration potential of tumor-infiltrating and peripheral-expanded Vgamma9Vdelta2 T cells from renal cell carcinoma patients.
    Viey E; Lucas C; Romagne F; Escudier B; Chouaib S; Caignard A
    J Immunother; 2008 Apr; 31(3):313-23. PubMed ID: 18317356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.